Medicinal – Page 6

A sense of the bigger picture: A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use

mycolabadmin

This research explored how 15 people with bipolar disorder who used psilocybin mushrooms experienced the effects. Many reported benefits like reduced depression and improved outlook on life, but some experienced negative effects including sleep problems and increased manic episodes. The study identified important factors that influenced outcomes, such as whether people used other drugs simultaneously, whether they used psilocybin alone or with others, and how much sleep they had before use. The researchers concluded that while psilocybin shows promise for bipolar depression, more careful clinical research is needed to ensure safety.

An Overview of Physiologically-Based Pharmacokinetic Models for Forensic Science

mycolabadmin

This review examines how mathematical models that predict how drugs and chemicals move through the body could be better used in forensic science to help explain cause of death and interpret toxicology evidence. Currently, only a few such models have been specifically developed for forensic purposes, though many exist for common drugs like opioids, cocaine, and alcohol. A major challenge is accounting for how drug concentrations change after death, which can make it harder to determine what the concentration was when the person died.

How Do Cyclodextrins and Dextrans Affect the Gut Microbiome? Review of Prebiotic Activity

mycolabadmin

Cyclodextrins and dextrans are substances commonly used in medicines that may have unexpected health benefits for your gut bacteria. Research shows these compounds can help beneficial bacteria like Lactobacillus and Bifidobacterium grow better in your digestive system. When these good bacteria ferment these substances, they produce helpful compounds called short-chain fatty acids that improve overall gut health and may help with conditions like obesity and inflammation.

Psychedelic Drugs or Hallucinogens: Exploring Their Medicinal Potential

mycolabadmin

Psychedelic drugs like LSD and psilocybin are substances that alter perception and consciousness. Research shows they may help treat serious mental health conditions including depression, anxiety, and PTSD by affecting how the brain forms new connections. These substances are relatively safe compared to many legal drugs, and scientists believe they could revolutionize mental health treatment when used properly under medical supervision.

Synthesis of fungal polysaccharide-based nanoemulsions for cancer treatment

mycolabadmin

Researchers developed tiny capsules (nanoemulsions) made from corn protein and chitosan to better deliver shiitake mushroom compounds to treat cancer and reduce inflammation. When shiitake extract was enclosed in these nano-sized carriers, it became much more effective at killing breast cancer cells, fighting bacteria, and reducing inflammation compared to using the mushroom extract alone. This technology could lead to new natural medicines and health supplements that are more effective at lower doses.

Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding

mycolabadmin

Researchers studied how psilocybin’s active form affects the brain’s fear center in both male and female rats. They found that a single dose produced different effects in males versus females, with males showing lasting reductions in fear responses over 28 days while females showed variable changes. These findings help explain why psychedelics might work differently between sexes and could inform how they’re used to treat anxiety and depression in humans.

CRISPR-Cas9 enables efficient genome engineering of the strictly lytic, broad-host-range staphylococcal bacteriophage K

mycolabadmin

Scientists have developed a new method to genetically engineer bacteriophages—viruses that infect bacteria—to fight antibiotic-resistant Staphylococcus aureus infections. Using CRISPR technology, they created a special phage that glows when it infects S. aureus cells, allowing doctors to quickly detect this dangerous pathogen in patient blood samples and other clinical samples. This engineered phage works against most S. aureus strains tested, regardless of their resistance to vancomycin, and could lead to new diagnostic tools and treatments for drug-resistant bacterial infections.

Large-Scale Field Cultivation of Morchella and Relevance of Basic Knowledge for Its Steady Production

mycolabadmin

Morels are valuable mushrooms worth hundreds of dollars per kilogram. China dramatically expanded morel farming from 2012 to 2022, but many farmers struggle with unstable harvests and profits. Scientists have discovered that successful morel cultivation requires careful attention to species selection, proper nutrition techniques, and understanding the complex mating systems of morel fungi. Better training and scientific knowledge could help make morel farming more reliable and profitable worldwide.

Psilocin, A Psychedelic Drug, Exerts Anticonvulsant Effects Against PTZ- and MES-Induced Seizures in Mice via 5-HT1A and CB1 Receptors: Involvement of Nitrergic, Opioidergic, and Kynurenine Pathways

mycolabadmin

Researchers tested psilocin, the active ingredient in magic mushrooms, and found it could reduce seizures in mice at low doses (3-5 mg/kg) without causing psychedelic effects. The anticonvulsant benefits were mediated through several brain pathways including serotonin, cannabinoid, opioid, and nitric oxide signaling systems. The effects persisted for at least 9 days after a single dose, suggesting psilocin may have potential as a new treatment for epilepsy, though human clinical trials are needed to confirm these findings.

A Terrible Trip: Tubulointerstitial Nephritis and Uveitis Syndrome Triggered by Psilocybe Mushroom Ingestion

mycolabadmin

A patient experienced serious kidney and eye inflammation after ingesting psilocybe mushrooms, which are known for their hallucinogenic properties. This rare combination of symptoms, called TINU syndrome, had not been previously associated with mushroom use. The case highlights an unexpected and serious health risk from consuming hallucinogenic mushrooms, suggesting that the active compounds may trigger severe inflammatory responses in some individuals.

Research Topic: Medicinal